Eledon Pharmaceuticals (ELDN) Cash & Equivalents (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Cash & Equivalents data on file, last reported at $6.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 95.07% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (down 95.07% YoY) and the FY2025 annual result came in at $22.8 million, up 10.99% from the prior year.
• Cash & Equivalents fell to $6.2 million in Q1 2026, from $22.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $124.9 million in Q1 2025 to a low of $3.7 million in Q3 2023.
• A 5-year average of $27.0 million and a median of $9.2 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents soared 2108.66% — and 2026, when it slumped 95.07%.
• Tracing ELDN's Cash & Equivalents over 5 years: stood at $56.4 million in 2022, then plunged by 91.82% to $4.6 million in 2023, then surged by 345.56% to $20.5 million in 2024, then climbed by 10.99% to $22.8 million in 2025, then sank by 73.03% to $6.2 million in 2026.
• The last three Cash & Equivalents figures came in at $6.2 million (Q1 2026), $22.8 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.